Inventor · disambiguated record
Eran Ophir
Also filed as: OPHIR ERAN
14 granted patents·14 pending applications·61 citations·filing 2009–2024
91Inventor score
Top patents by PatentIndex Score
28 records- 0193US12508307B2Genetically modified anti-third party central memory T cells and use of same in immunotherapyYEDA RES & DEV·Filed 2023·Granted Dec 30, 2025·1 cites·20 claims
- 0293US10124061B2Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereofCOMPUGEN LTD·Filed 2017·Granted Nov 13, 2018·9 cites·20 claims
- 0392US10751415B2Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereofCOMPUGEN LTD·Filed 2017·Granted Aug 25, 2020·6 cites·22 claims
- 0492US10213505B2Anti-TIGIT anibodies, anti-PVRIG antibodies and combinations thereofCOMPUGEN LTD·Filed 2018·Granted Feb 26, 2019·6 cites·2 claims
- 0591US11179448B2Genetically modified anti-third party central memory T cells and use of same in immunotherapyYEDA RES & DEV·Filed 2016·Granted Nov 23, 2021·5 cites·15 claims
- 0689US11844827B2Genetically modified anti-third party central memory T cells and use of same in immunotherapyYEDA RES & DEV·Filed 2021·Granted Dec 19, 2023·1 cites·18 claims
- 0789US10933124B2Methods of transplantation and disease treatmentYEDA RES & DEV·Filed 2016·Granted Mar 2, 2021·4 cites·31 claims
- 0889US9421228B2Use of anti third party central memory T cells for anti-leukemia/lymphoma treatmentREISNER YAIR·Filed 2011·Granted Aug 23, 2016·12 cites·19 claims
- 0988US9738872B2Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatmentREISNER YAIR·Filed 2009·Granted Aug 22, 2017·12 cites·22 claims
- 1087US11225523B2Triple combination antibody therapiesCOMPUGEN LTD·Filed 2018·Granted Jan 18, 2022·3 cites·11 claims
- 1183US11701424B2Anti-TIGIT antibodies, anti-PVRIG antibodies and combinations thereofCOMPUGEN LTD·Filed 2020·Granted Jul 18, 2023·1 cites·30 claims
- 1281US11324777B2Anti third party central memory T cells, methods of producing same and use of same in transplantation and disease treatmentYEDA RES & DEV·Filed 2017·Granted May 10, 2022·1 cites·18 claims
- 1380US2025136710A1Triple combination antibody therapiesCOMPUGEN LTD·Filed 2024·Application pending·0 cites
- 1479US2024139318A1Anti-tigit antibodies, anti-pvrig antibodies and combinations thereofCOMPUGEN LTD·Filed 2023·Application pending·0 cites
- 1575US12133866B2Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatmentYEDA RES & DEV·Filed 2022·Granted Nov 5, 2024·0 cites·19 claims
- 1674US12152084B2Triple combination antibody therapiesCOMPUGEN LTD·Filed 2021·Granted Nov 26, 2024·0 cites·12 claims
- 1765US2024425607A1Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancerCOMPUGEN LTD·Filed 2024·Application pending·0 cites
- 1863US2025297018A1Il-18bp antagonist antibodies and their use in monotherapy and combination therapy in the treatment of cancerCOMPUGEN LTD·Filed 2023·Application pending·0 cites
- 1961US2025339522A1Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodiesCOMPUGEN LTD·Filed 2022·Application pending·0 cites
- 2060US2024103010A1Pvrl2 and/or pvrig as biomarkers for treatmentCOMPUGEN LTD·Filed 2023·Application pending·0 cites
- 2157US2024082397A1Anti-pvrig antibodies formulations and uses thereofCOMPUGEN LTD·Filed 2022·Application pending·0 cites
- 2257US2025382364A1Anti-tigit and anti-pvrig in monotherapy and combination treatmentsCOMPUGEN LTD·Filed 2022·Application pending·0 cites
- 2356US2023365680A1Combination therapy with anti-pvrig antibodies formulations, anti-tigit antibodies, and anti-pd-1 antibodiesCOMPUGEN LTD·Filed 2021·Application pending·0 cites
- 2454US2024076373A1Combination therapy with anti-pvrig antibodies formulations and anti-pd-1 antibodiesCOMPUGEN LTD·Filed 2022·Application pending·0 cites
- 2554US2023400467A1Pvrl2 and/or pvrig as biomarkers for treatmentCOMPUGEN LTD·Filed 2021·Application pending·0 cites
- 2651US2014212398A1Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatmentREISNER YAIR·Filed 2012·Application pending·0 cites
- 2748US2016354410A1Use of anti third party central memory t cells for anti-leukemia/lymphoma treatmentYEDA RES & DEV·Filed 2016·Application pending·0 cites
- 2845US2023057899A1Anti-pvrig and anti-tigit antibodies for enhanced nk-cell based tumor killingCOMPUGEN LTD·Filed 2020·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Eran Ophir files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →